In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates Confront the Limits of Traditional Rehab
ASPEN, Colorado β The drive into the Aspen Meadows Resort, with its open mountain views and Bauhaus-inspired architecture, offered a tranquil approach to what became one of the most strategically focused psychedelic policy gatherings of the year. Inside, at the Americans for Ibogaine (AFI) convening, the mood was not utopian but pragmatic β a coalition [β¦] The post In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates Confront the Limits of Traditional Rehab appeared first on Psychedelics Today.
External link. We are not responsible for the content.
Read more βMore From Psychedelics Today
Inclius Alvariousβs Place Within Indigenous Society
A look at Sonoran Desert toad medicine through the lens of indigenous sovereignty, ecological strain, and the debate ...
Shane Mauss β Comedy and Molecules β Episode 14
Shane Mauss is an award-winning comedian (Conan, Kimmel, Comedy Central, Prime) with a fondness for interviewing scie...
Ketamine-Assisted Couple Therapy Training by Enamory
This educational workshop is the first step toward certification in the Enamory model of Ketamine-Assisted Couple The...
Latest News
Where Does the World Go to Dance? Probs These EDM Festivals
A global guide to the festivals worth planning for. [...] Read More... The post Where Does the World Go to Dance? Pro...
Can you kill a bad trip?: 5 Questions for emergency physician Gregory Yates
Yates discusses experimental attempts to end a psychedelic trip early.
Psychedelic Faeries Take on Prohibition and Authoritarianism
Plus psychedelics and telepathy, ego death for the rich, and our brain on Chat GPT [...] Read More... The post Psyche...
Introduction to Trip Sitting
The Art and Science of Holding Psychedelic Space
Heartbreak is a Bad Trip
Oli Genn-Bash describes how the aftermath of a sudden breakup felt like a prolonged βbad tripβ, as well as the potent...
New Orleans Hosts Psychedelic Research Conference Double-Header
Over the last week in February, more than 200 people from psychedelic drug development companies, clinical researcher...